Medical Device Network on MSN
Alcon spends up to $200M to co-develop customisable cataract lenses with RxSight
The companies will combine their expertise to develop a ‘tuneable’ presbyopia-correcting intraocular lens (PCIOL) for cataract patients.
BENGALURU, India--(BUSINESS WIRE)--Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the launch of the Clareon ® Family of intraocular ...
Aziz Mottiwala becomes RxSight CEO July 20 amid commercial challenges. The move follows the $200M Alcon deal for adjustable ...
Milestone includes more than 6 million PCIOL implants worldwide, with PanOptix and Vivity leading globally in trifocal and EDOF IOLs1,* PanOptix delivers outstanding patient satisfaction and freedom ...
PanOptix delivers an exceptional combination of near, intermediate and distance vision and substantially reduces the need for glasses 1,2 More than ninety-nine percent of PanOptix patients in the FDA ...
MarketBeat on MSN
RxSight Q2 sales sink 20% as Alcon deal bolsters 2026 outlook
Key Points Interested in RxSight, Inc.? Here are five stocks we like better. RxSight's preliminary Q2 sales fell 20% year over year to about $27 million excluding collaboration revenue, with Light ...
Please provide your email address to receive an email when new articles are posted on . The Clareon family of IOLs is now available in the U.S., with an international rollout set to take place ...
Narrow-moat Alcon ALC reported second-quarter earnings that were ahead of our expectations. Total sales were up 9.2% year over year as strong performance from both surgical and visioncare units ...
Clareon PanOptix, which delivers exceptional clarity and offers spectacle independence across all distances with a patient satisfaction rate of 99.2%31-34; PanOptix® Trifocal IOL, implanted over 2.2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results